[-] Show simple item record

dc.contributor.authorAlbrecht, Angela M.eng
dc.contributor.authorPaulson, Christopher P.eng
dc.contributor.authorKovach, Fran E.eng
dc.date.issued2009eng
dc.description.abstractRecombinant human thyrotropin (rhTSH)-stimulated serum thyroglobulin (Tg) level alone is sufficient to monitor for recurrent disease in low-risk patients with a history of differentiated thyroid cancer (DTC) (strength of recommendation [SOR] A, meta-analysis). Low-risk patients are defined as patients who have undergone total thyroidectomy and radioactive iodine (I131) remnant ablation therapy and show no clinical evidence of recurrent disease.eng
dc.identifier.urihttp://hdl.handle.net/10355/4004eng
dc.languageEnglisheng
dc.publisherFamily Physicians Inquiries Networkeng
dc.relation.ispartofcollectionClinical Inquiries, 2009 (MU)eng
dc.relation.ispartofcommunityUniversity of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Networkeng
dc.relation.ispartofseriesJournal of family practice, 58, no. 12 (December 2009): 676d-676f.eng
dc.rightsOpenAccess.eng
dc.rights.licenseThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivs 3.0 License.eng
dc.subjectpapillary carcinomaeng
dc.subjectfollicular carcinomaeng
dc.subjectthyroid remnant ablationeng
dc.subject.lcshThyroid gland -- Cancer -- Patients -- Careeng
dc.subject.lcshThyroglobulineng
dc.subject.lcshWhole body imagingeng
dc.titleWhat's the best way to monitor low-risk patients with a history of differentiated thyroid cancer?eng
dc.typeArticleeng


Files in this item

[PDF]

This item appears in the following Collection(s)

[-] Show simple item record